Aytu BioPharma, Inc.
AYTU · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | 0.00 | -0.03 |
| FCF Yield | -37.73% | -10.88% | -95.98% | -142.08% |
| EV / EBITDA | -1.22 | 8.67 | -3.91 | -0.68 |
| Quality | ||||
| ROIC | -11.19% | -3.12% | -22.00% | -142.42% |
| Gross Margin | 69.04% | 75.26% | 62.04% | 52.02% |
| Cash Conversion Ratio | 0.14 | 0.09 | 0.30 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.82% | -12.31% | 17.84% | 51.81% |
| Free Cash Flow Growth | -200.82% | 66.52% | 82.21% | -11.01% |
| Safety | ||||
| Net Debt / EBITDA | 1.72 | -2.55 | -2.27 | 0.04 |
| Interest Coverage | -2.11 | -0.33 | -3.44 | -0.75 |
| Efficiency | ||||
| Inventory Turnover | 1.80 | 1.33 | 3.40 | 4.28 |
| Cash Conversion Cycle | 186.10 | 173.08 | 85.07 | 80.89 |